Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $567,664.20 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew Posard sold 5,230 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $108.54, for a total transaction of $567,664.20. Following the transaction, the director directly owned 53,609 shares in the company, valued at $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $109.86 on Monday. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $116.85. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a 50-day simple moving average of $103.50 and a two-hundred day simple moving average of $81.57. The company has a market capitalization of $12.47 billion, a price-to-earnings ratio of 32.79, a PEG ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter last year, the business posted $1.54 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on HALO shares. TD Cowen upped their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st. Citizens Jmp boosted their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, HC Wainwright restated a “buy” rating and set a $115.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, September 2nd. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Institutional Trading of Halozyme Therapeutics

Large investors have recently bought and sold shares of the company. Bank of America Corp DE purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 2nd quarter worth about $196,540,000. Royal London Asset Management Ltd. increased its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after acquiring an additional 200,262 shares during the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics in the 4th quarter valued at about $128,201,000. Finally, Jupiter Topco LLC purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $105,570,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.